Advertisement

Picture [iito] Made Without Love 650x80px
Document › Details

Heidelberg Pharma AG. (4/27/20). "Press Release: Heidelberg Pharma AG Raises EUR 14.4 Million from Private Placement". Ladenburg.

Organisations Organisation Heidelberg Pharma AG (FSE: WL6)
  Group Heidelberg Pharma (Group)
  Organisation 2 Dievini Hopp BioTech Holding GmbH & Co. KG
  Group HOPP Group (family of Dietmar Hopp)
Products Product HDP-101 (Heidelberg Pharma)
  Product 2 investment banking
Index term Index term Heidelberg Pharma–SEVERAL: investment, 202004 private placement €14.4m with 2.82m new shares at €5.1/share incl €13.7m from Dievini Hopp
Persons Person Hopp, Dietmar (SAP)
  Person 2 Wimmer, Sylvia (Wilex 201403 Corporate Communications)
     


Ad hoc announcement
Inside information pursuant to Article 17 MAR


Heidelberg Pharma AG (FSE: WL6) announces that it has successfully raised approximately EUR 14.4 million in gross proceeds through a private placement via an accelerated book building transaction. Heidelberg Pharma issued 2,820,961 new shares from authorized capital, which corresponds to approximately 10% of the current share capital. Of these, 2,679,961 shares were allocated to the main investor dievini Hopp Biotech holding GmbH & Co. KG, Walldorf, (dievini) as well as 141,000 shares to institutional investors at a price of EUR 5.10 per share, which represents a discount of approximately 5% to the daily closing price. The capital measure will increase the total number of registered shares after the issuance to 31,030,572.

The issuance of new shares was resolved today by the Management Board and Supervisory Board of Heidelberg Pharma AG. The new shares will be admitted to trading on the Frankfurt Stock Exchange after the capital increase has been entered in the commercial register.

The capital increase has been executed by MainFirst Bank AG, Kennedyallee 76, 60596 Frankfurt, Germany, acting as global coordinator and sole bookrunner.


Important notes

This ad hoc announcement does not constitute an offer to sell or a solicitation to buy securities. Specifically, this document does not constitute an offer to sell securities or the solicitation to submit an offer to buy securities in the United States of America, Canada, Japan and Australia. The shares of Heidelberg Pharma AG (the “Shares”) may not be offered or sold in the United States of America or to or for the account or benefit of “U.S. persons” (as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”)), unless they have been registered or are exempt from registration under the Securities Act. The shares have not been and will not be registered under the Securities Act. There will be no public offer of shares in the United States of America, Canada, Japan and Australia.


+++ End of the ad hoc announcement +++


About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.


Contact

Heidelberg Pharma AG
Sylvia Wimmer
Tel.: +49 89 41 31 38-29
Email: investors[at]hdpharma.com
Schriesheimer Str. 101, 68526 Ladenburg


IR/PR support

MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 210 228-40
Email: katja.arnold[at]mc-services.eu


This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

   
Record changed: 2020-05-16

Advertisement

Picture [iito] – Putting Information into Context 650x65px

More documents for Heidelberg Pharma (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top